SPRY
ARSDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
The constructive case is that neffy still has broad access, a lower-spend plan, Florida Medicaid expansion effective July 1, and management continues to argue the base business can reach cash-flow breakeven in 2027 if refill behavior and back-to-school demand strengthen as expected. [#IR-2026-06-24] [#SEC-8K-2026-05-15]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.3.
What can break
CSU pipeline value is still pre-readout and cannot yet offset core commercial risk if neffy uptake slows. [#SEC-8K-2026-05-15]
Momentum
5
Value
41
Sentiment
92
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $16.00 · Bear $5.50
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $26.75
Why
Momentum5 · Δ7d -16.3
Value41 · Δ7d -0.1
Sentiment92 · Δ7d +1.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
5
26% active weight
Current posture
7d trendSoftening
Δ7d
-16.3
Δ21d
-75.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
92
34% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-16.3
Why this grade
Composite grade D. Momentum 4.9 / Value 41.1 / Sentiment 91.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$695.12M
Beta
0.79
Shares Out
99.3M
P/E (TTM) · Derived
-4.0
P/S (TTM)
7.60
P/FCF (TTM)
83.51
Rev YoY
+184.5%
EPS YoY
+76.4%
Gross Margin
+74.1%
Op Margin
-63.6%
Net Debt
-$148.02M
Current Ratio
4.94
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology